This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
T-DXd
JSMO 2025 | March 6-8, 2025
Efficacy of trastuzumab deruxtecan and biomarker changes in HER2-positive gastric cancer: EN-MARK study protocol
Oral
Other/Multi
JSMO 2025 | March 6-8, 2025
Expression of tumor-associated mucin 1 in bladder and upper urinary tract cancers
Oral
I-DXd
JSMO 2025 | March 6-8, 2025
IDeate-Lung01: A phase 2 trial of ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer
Poster
I-DXd
JSMO 2025 | March 6-8, 2025
IDeate-Lung02: Phase 3 study of ifinatamab deruxtecan (I-DXd) in relapsed small cell lung cancer
Poster
I-DXd
JSMO 2025 | March 6-8, 2025
Ifinatamab deruxtecan (I-DXd) + atezolizumab ± carboplatin as first-line therapy for extensive-stage small cell lung cancer
Mini-Oral
T-DXd
JSMO 2025 | March 6-8, 2025
Olanzapine-based triplet antiemetic therapy for patients undergoing trastuzumab deruxtecan: ERICA (WJOG14320B)
Mini-Oral
T-DXd
JSMO 2025 | March 6-8, 2025
Prognostic factors for T-DXd treatment in HER2+ unresectable advanced/recurrent gastric cancer: EN-DEAVOR sub-analysis
Oral
T-DXd
JSMO 2025 | March 6-8, 2025
Real-world analysis of interstitial lung disease/pneumonitis
in patients with HER2-positive unresectable or recurrent
breast cancer treated with trastuzumab deruxtecan:
All-patient post-marketing surveillance study in Japan
Poster
T-DXd
JSMO 2025 | March 6-8, 2025
Real-world HER2-positive unresectable or metastatic breast cancer treatment patterns and outcomes in China
Oral
T-DXd
JSMO 2025 | March 6-8, 2025
T-DXd in HER2+ advanced/metastatic breast cancer patients with/without brain metastases: Results from DESTINY-Breast12
Pages:
1 2